Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

63.97 -0.67 (-1.04%)
Streaming Delayed Price Updated: 2:17 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
1 Healthcare Stock Worth Investigating and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
Via The Motley Fool
Exact Sciences Earns 2025 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance. 
Via Benzinga
Exact Sciences (EXAS) Stock Trades Up, Here Is Why
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 15.2% in the morning session after the company reported strong first quarter 2025 results which beat analysts' revenue and... 
Via StockStory
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance
Exact Sciences posted better-than-expected Q1 results and lifted its 2025 outlook, signaling confidence in growth and operational momentum. 
Via Benzinga
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Exact Sciences (NASDAQ:EXAS) Posts Better-Than-Expected Sales In Q1, Stock Soars
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue... 
Via StockStory
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Exact Sciences Hikes Its Full-Year Outlook. But There's One First-Quarter Drawback.
The company hiked its sales guidance for the year, but reported steeper-than-expected first-quarter losses. 
Via Investor's Business Daily
Topics Government
Exact Sciences Announces First-Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences (EXAS) Reports Q1: Everything You Need To Know Ahead Of Earnings
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting results tomorrow after the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
From Exact Sciences Corp.
Via Business Wire
2 Reasons to Like EXAS (and 1 Not So Much)
What a brutal six months it’s been for Exact Sciences. The stock has dropped 37.2% and now trades at $44.10, rattling many shareholders. This may have investors wondering how to approach the... 
Via StockStory
Exact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s Optimistic
Patients who test positive for circulating tumor DNA with the Oncodetect test during surveillance are 50 times more likely to experience cancer recurrence than those with negative results, the company... 
Via Stocktwits
Topics Government
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
From Exact Sciences Corp.
Via Business Wire
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
From Exact Sciences Corp.
Via Business Wire
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
2 Oversold Stocks Ready to Bounce Back and 1 to Approach with Caution
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings)
 
Via Benzinga
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
Exact Sciences Schedules First Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.